The Medicare Bridge Copay Reality After 60 Days of Enrollment Data
The Medicare BALANCE / Bridge Model launched in July 2026 with promises of $50/month copays for eligible beneficiaries. Sixty days into enrollment, the real experience has clarified. Here's what the copay reality actually looks like for patients who've enrolled.
The Bridge Structure
The Medicare Bridge Model offers eligible beneficiaries access to Wegovy or Zepbound at a negotiated drug price of approximately $245/month, with beneficiary copays targeted at $50/month. Eligibility requires: BMI ≥27 with prediabetes or cardiovascular disease history, BMI ≥30 with heart failure, hypertension, or chronic kidney disease, or BMI ≥35 without additional comorbidity.
Enrollment Experience
Real enrollment has been more paperwork-heavy than the launch messaging suggested. Documentation of eligibility (BMI, comorbidities, prior weight loss attempts) requires records from the beneficiary's primary care physician. Prior authorization is required even under the Bridge Model. Approval timelines have run 2-6 weeks depending on documentation completeness.
Found Health
Brand-name GLP-1 access with coaching layer.
- Brand-name focus
- Coaching + accountability
- Insurance-coordinated model
Copay Reality
For approved beneficiaries, the $50/month copay is landing as advertised in most cases. Some beneficiaries with supplemental coverage or specific plan structures have seen lower copays (as low as $25); others with certain plan configurations have seen slightly higher costs.
The dramatic contrast is against pre-Bridge Medicare: before this model, most Medicare beneficiaries had zero coverage for GLP-1s for weight-loss indications, meaning $349-$450/month cash-pay via NovoCare/LillyDirect or no access at all. Moving to $50/month is real financial change for the population that qualifies.
Sesame Care
Marketplace for brand-name, FDA-approved GLP-1 prescriptions only.
- Brand-name only (no compounded)
- Direct-to-patient consult marketplace
- Cash-pay clarity
Who Isn't Getting Approved
Beneficiaries who've been denied Bridge coverage typically fall into: BMI at 26-27 with no qualifying comorbidity, documentation gaps in comorbidity records, or beneficiaries in plans that haven't fully implemented Bridge enrollment yet. Appeals processes exist but add weeks to timeline.
Oak Weight Loss
Telehealth program with compounded GLP-1 access.
- Compounded semaglutide/tirzepatide
- Standard telehealth intake
- Membership-style pricing
Care Bare Rx
Telehealth prescribing with compounded fulfillment.
- Compounded GLP-1 options
- Weight-loss intake funnel
- Verify pricing at intake
For Beneficiaries Who Don't Qualify
Medicare beneficiaries who don't qualify for Bridge have the same alternatives as non-Medicare patients: NovoCare or LillyDirect cash-pay programs, compounded pharmacy pathways, or (in some cases) advocacy for Medicare Advantage plans that include weight-loss GLP-1 coverage beyond Bridge criteria. Compounded programs specifically don't interface with Medicare and are entirely cash-pay for beneficiaries who go that route.
Embody
Lead compounded-injectable option with a $400 CPA tier.
- Injectable semaglutide only
- Standard titration schedule
- Direct pharmacy fulfillment
MadeMed
Independent compounder — compounded oral tirzepatide.
- Compounded oral tirzepatide
- $167–$229 range by dose tier
- Direct pharmacy fulfillment
The 60-Day Assessment
The Bridge Model works as designed for the beneficiaries it was designed for. Where it works, the copay reduction is transformative. Where it doesn't (eligibility gaps, documentation friction), the pre-Bridge cash-pay landscape still applies. Sixty days of data suggests the model will expand and streamline over time — but current-quarter beneficiaries should plan around the current documentation requirements rather than assuming smoother enrollment ahead.
Wellorithm
Compounded GLP-1 with dose-tier pricing.
- Sema and tirz options
- Tier pricing by dose
- Verify at intake
Telos Rx
Compounded tirzepatide via direct pharmacy program.
- Compounded tirzepatide focus
- Direct-link intake format
- Verify current pricing at intake
Where to Start
Sesame Care
Marketplace for brand-name, FDA-approved GLP-1 prescriptions only.
- Brand-name only (no compounded)
- Direct-to-patient consult marketplace
- Cash-pay clarity
Found Health
Brand-name GLP-1 access with coaching layer.
- Brand-name focus
- Coaching + accountability
- Insurance-coordinated model
Embody
Lead compounded-injectable option with a $400 CPA tier.
- Injectable semaglutide only
- Standard titration schedule
- Direct pharmacy fulfillment